Worldwide Clinical Trials Expands Leadership Team to Enhance Global Reach and Therapeutic Expertise
Worldwide Clinical Trials, a global contract research organization (CRO) focused on delivering specialized clinical development services for the biopharmaceutical and medical device industries, has announced a series of major leadership appointments aimed at strengthening its therapeutic expertise, regional presence, and operational execution capabilities. The appointments come at a pivotal time for the organization as the clinical research landscape continues to evolve rapidly, driven by increasingly complex trial designs, precision medicine approaches, and rising demand for global clinical development support.
The company has named Dr. Panteli Theocharous as Chief Therapeutics & Clinical Strategy Officer and President of Europe, Marcin Ernst as President of Internal Medicine, Keya Watkins as President of Oncology, and Gijsbert Veerman as Vice President of Early Phase Oncology – Europe. Together, these senior executives bring decades of experience across biotechnology, pharmaceutical development, clinical operations, oncology, rare disease research, and international regulatory strategy.
The expanded leadership structure also reflects Worldwide’s continued growth strategy following its recent acquisition of Catalyst Clinical Research, a move that significantly broadened the company’s oncology capabilities and global service footprint. By integrating experienced therapeutic leaders and strengthening regional oversight, Worldwide aims to enhance its ability to support sponsors conducting increasingly sophisticated clinical trials across multiple therapeutic areas and geographies.
According to Worldwide Chief Executive Officer Alistair Macdonald, the latest appointments reinforce the organization’s long-term commitment to operational excellence and scientific rigor in clinical development.
Macdonald emphasized that the addition of highly experienced leaders in strategically important regions and therapeutic disciplines will help Worldwide continue delivering advanced clinical trial programs for biotechnology and pharmaceutical companies worldwide. He noted that the combined expertise of the new executives, alongside the integration of Catalyst Clinical Research, strengthens the organization’s ability to support sponsors with scalable infrastructure, scientific insight, and consistent execution across global studies.
The appointments arrive during a period of substantial transformation in the CRO sector. Sponsors are increasingly outsourcing complex clinical programs that involve advanced therapeutics such as cell and gene therapies, targeted oncology treatments, immunotherapies, and rare disease medicines. At the same time, regulatory expectations and operational demands continue to increase, creating the need for CRO partners with deep therapeutic specialization and strong regional leadership.
One of the most significant appointments is that of Dr. Panteli Theocharous. A biotech entrepreneur and veteran clinical development executive, Theocharous brings more than 35 years of international experience in clinical research and drug development. Over the course of his career, he has worked across multiple therapeutic disciplines and played a key role in the development of complex therapeutic modalities, including advanced cell and gene therapies.
In his dual leadership role, Theocharous will oversee Worldwide’s therapeutic and clinical strategy initiatives while also leading the company’s European operations. The role is designed to strengthen integration between scientific strategy and operational delivery, enabling sponsors to better align clinical and commercial objectives throughout the drug development process.
His appointment is particularly important as Europe continues to play a central role in global clinical research, especially in oncology, rare disease, and precision medicine programs. The region offers strong academic research networks, experienced investigators, and increasingly important regulatory pathways that support innovative therapies. Theocharous is expected to help expand Worldwide’s European capabilities while ensuring globally integrated development strategies for clients conducting multinational studies.
Worldwide also appointed Marcin Ernst as President of Internal Medicine. Ernst brings more than two decades of clinical research experience gained across both sponsor organizations and CRO environments. Prior to joining Worldwide, he served at Ora Clinical, where he held leadership positions as Senior Vice President of Clinical Development Operations and Vice President of Ora Europe.
Ernst’s background combines medical expertise with operational leadership, an increasingly valuable combination as internal medicine studies grow more complex and geographically dispersed. His experience includes overseeing global clinical development programs, operational strategy, and cross-functional execution for a range of therapeutic areas.
At Worldwide, Ernst will focus on enhancing delivery execution and strengthening organizational alignment across internal medicine programs. The company believes his leadership will improve consistency, operational quality, and sponsor support, particularly throughout Europe where clinical trial activity continues to expand.
The oncology division also received a significant leadership enhancement with the appointment of Keya Watkins. Watkins joined Worldwide through the company’s acquisition of Catalyst Clinical Research and brings nearly 30 years of oncology and hematology drug development experience spanning both biopharmaceutical companies and CRO organizations.
Her expertise includes managing large, multidisciplinary oncology programs and helping sponsors navigate the increasingly demanding requirements associated with cancer drug development. Oncology remains one of the fastest-growing segments within the global clinical trial market, fueled by advances in immunotherapy, targeted therapies, antibody-drug conjugates, bispecific antibodies, and personalized medicine approaches.
Under Watkins’ leadership, Worldwide aims to further strengthen its oncology strategy and operational capabilities. Her role includes supporting sponsors through complex global oncology studies by improving consistency, accelerating execution timelines, and leveraging deep therapeutic expertise across development stages.
The integration of Catalyst Clinical Research into Worldwide’s broader oncology infrastructure provides additional scale and experience in oncology trial management. Industry observers view oncology specialization as a critical differentiator among CROs, particularly as clinical trials become more biomarker-driven and operationally sophisticated.
Further expanding Worldwide’s oncology expertise, Gijsbert Veerman has been appointed Vice President of Early Phase Oncology – Europe. Veerman brings nearly 30 years of experience in early oncology drug development and previously served as Chief Operating Officer at IQVIA Biotech.
His background includes extensive experience supporting first-in-human trials, dose escalation studies, translational medicine programs, and early-stage oncology development strategies. Early phase oncology research has become increasingly specialized due to the growing complexity of targeted therapies and the need for precision biomarker integration.
At Worldwide, Veerman will help strengthen the organization’s capabilities in early development oncology programs, particularly within European regulatory environments. His expertise in therapeutic strategy and regulatory pathways is expected to support sponsors seeking efficient progression through early clinical development stages.
The broader strategic importance of these appointments reflects ongoing shifts within the global CRO industry. Pharmaceutical and biotechnology companies are increasingly seeking partners capable of delivering both scientific expertise and operational scalability. Sponsors now require CROs that can provide integrated support across early development, late-stage trials, regulatory planning, and commercialization strategy.
At the same time, regional leadership has become increasingly important. Europe remains a major hub for innovative clinical research, with strong infrastructure for oncology, rare disease, and advanced therapy trials. By strengthening its European leadership team, Worldwide positions itself to better support sponsors navigating diverse regulatory systems, site networks, and patient recruitment challenges across the region.
The company’s focus on therapeutic specialization also aligns with broader industry trends. Modern clinical development increasingly depends on deep scientific understanding within targeted therapeutic areas rather than generalized operational support alone. Oncology, internal medicine, rare diseases, and cell and gene therapies each require highly specialized expertise in protocol design, patient selection, biomarker strategies, and regulatory interactions.
Worldwide’s leadership expansion demonstrates its intention to compete aggressively in these high-growth segments of the CRO market. The company continues investing in both scientific leadership and operational infrastructure to support biotechnology startups, mid-sized biopharmaceutical firms, and large pharmaceutical sponsors pursuing innovative therapies.
As clinical research becomes more globalized and technically demanding, CROs capable of combining regional expertise, therapeutic specialization, and operational consistency are likely to play an increasingly central role in the drug development ecosystem. Worldwide’s latest appointments signal a strategic effort to strengthen those capabilities while expanding its position within the increasingly competitive global clinical research market.
About Worldwide Clinical Trials:
Worldwide Clinical Trials (“Worldwide”) is a global CRO serving development-driven biopharmaceutical companies, with more than 4,400 professionals operating across more than 70 countries. The company delivers therapeutically dedicated expertise in neuroscience, oncology, rare disease, and internal medicine, with comprehensive support across every development phase – from early-stage and first-in-human studies through Phase III registration trials.
The company’s flexible service model – spanning full-service trial management to functional service partnerships through Worldwide Flex – is powered by a people‑first, partnership‑driven outsourcing approach that strengthens collaboration, enhances data transparency, and supports more informed decision‑making. This provides sponsors with tailored, adaptable solutions that keep pace with the evolving demands of clinical research. Learn more at www.worldwide.com.
